Core2 β-1,6-<i>N</i>-acetylglucosaminyltransferase-1 expression correlates with prostate cancer progression.

<p>(<b>A</b>) Biosynthetic pathways for <i>O</i>-glycans. (<b>B</b>) PCa specimens were incubated with an anti-core2 β-1,6-<i>N</i>-acetylglucosaminyltransferase-1 (GCNT1) monoclonal antibody (mAb), followed by a horseradish peroxidase (HRP)-conjugated secondary antibody. Counterstaining was performed using hematoxylin. GCNT1-positive cancer cells are brown. (<b>C</b>) Prostate-specific antigen-free survival periods were compared between GCNT1-positive and GCNT1-negative specimens. Survival was analyzed using Kaplan-Meier curves.</p

Logistic regression analyses of risk factors for extracapsular extension of prostate cancer.

<p>^a; pre-treatment prostate-specific antigen</p><p>^b; Gleason score</p><p>CI, confidence interval; GCNT1, core2 β-1,6-<i>N</i>-acetylglucosaminyltransferase-1; HR, hazard ratio; PSA, prostate-specific antigen</p><p>Logistic regression analyses of risk factors for extracapsular extension of prostate cancer.</p

Detection of core2 β-1,6-<i>N</i>-acetylglucosaminyltransferase-1 in post-digital rectal examination urine specimens.

<p>(<b>A</b>) Post-digital rectal examination urine specimens were collected and (<b>B</b>) centrifuged. (<b>C</b>) Supernatants were collected and spotted onto a nitrocellulose membrane. (<b>D</b>) Core2 β-1,6-<i>N</i>-acetylglucosaminyltransferase-1 (GCNT1) was detected by an anti-GCNT1 monoclonal antibody, followed by a horseradish peroxidase (HRP)-conjugated antibody. (<b>E</b>) After treatment with a chemiluminescence reagent, the GCNT1 signal was recorded by a ChemiDoc+ system.</p

Univariate and multivariable analyses of risk factors for prostate-specific antigen recurrence.

<p>^a, pre-treatment prostate-specific antigen</p><p>^b, Gleason score</p><p>^c, cancer existence at the resected margin</p><p>^d, perineural invasion</p><p>^e, extracapsular extension</p><p>CI, confidence interval; GCNT1, core2 β-1,6-<i>N</i>-acetylglucosaminyltransferase-1; HR, hazard ratio; PSA, prostate-specific antigen.</p><p>Univariate and multivariable analyses of risk factors for prostate-specific antigen recurrence.</p

Prostate-specific antigen concentration and core2 β-1,6-<i>N</i>-acetylglucosaminyltransferase-1 expression predict extracapsular extension of prostate cancer.

<p>(<b>A</b>) Prostate-specific antigen (PSA) concentration and (<b>B</b>) Core2 β-1,6-<i>N</i>-acetylglucosaminyltransferase-1 (GCNT1) expression levels were significantly higher in prostate cancer (PCa) patients with extracapsular extension than in patients with organ-confined disease. (<b>C</b>) Receiver-operator characteristic curve analysis of PSA and GCNT1 revealed that the area under the curve of PSA was 0.7455 and GCNT1 was 0.7614. (<b>D</b>) Risk stratification was established using PSA and GCNT1 to predict the outcome of local PCa. Double negative (DN)-risk (PSA < 7.52 ng/mL, GCNT1< 79.36 pg/mg), single positive (SP)-risk (PSA > 7.52 ng/mL or GCNT1 > 79.36 pg/mg) and double positive (DP)-risk (PSA > 7.52 ng/mL and GCNT1 > 79.36 pg/mg) patients are compared.</p